Diffuse Large B-Cell Lymphoma (Dlbcl) Therapeutics Market 2024-2028
Technavio has been monitoring the diffuse large b-cell lymphoma (DLBCL) therapeutics market and is forecast to grow by USD 2249.8 mn during 2023-2028, accelerating at a CAGR of 8.09% during the forecast period. Our report on the diffuse large b-cell lymphoma (DLBCL) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, increasing incidence of DLBCL, and increasing approval of therapeutics for patients with relapsed or refractory DLBCL.
Technavio's diffuse large b-cell lymphoma (DLBCL) therapeutics market is segmented as below:
By Application
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Others
By Product
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the technological advances as one of the prime reasons driving the diffuse large b-cell lymphoma (DLBCL) therapeutics market growth during the next few years. Also, increasing patient support programs and strategic alliances will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the diffuse large b-cell lymphoma (DLBCL) therapeutics market covers the following areas:
- Diffuse large b-cell lymphoma (DLBCL) therapeutics market sizing
- Diffuse large b-cell lymphoma (DLBCL) therapeutics market forecast
- Diffuse large b-cell lymphoma (DLBCL) therapeutics market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading diffuse large b-cell lymphoma (DLBCL) therapeutics market vendors that include AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the diffuse large b-cell lymphoma (DLBCL) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.